Inhalation Sciences signs R&D order worth 257,000 SEK with major generic pharma company

Inhalation Sciences AB (ISAB) has signed a new R&D contract worth 257,000 SEK (23,200 Euros) for Inhalation Research Services (IRS) work for a returning, long-standing customer – a major branded generic pharma company.  

A long-standing customer of ISAB’s research services and instruments is outsourcing research and development work worth 257,000 SEK to ISAB during a peak in their development activities.

The work will be carried out using ISAB’s flexible, multi-modular PreciseInhale aerosol generation system that enables precision dosing of a range of in vitro and in vivo exposure modules.

ISAB CEO Manoush Masarrat: “We are happy to continue work with this valued customer who have such great confidence in the unique benefits and flexibility that PreciseInhale bring to their project.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale^® and Dissolv It^® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 23 December 2022.